You are here: Home: Audio Program Guide: NHLU 1 2007 Audio: NHLU 1 | 2007
 
  Go to interview with Andrew D Zelenetz, MD, PhD
Go to interview with John P Leonard, MD
Go to Interview with David G Maloney, MD, PhD

 

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Zelenetz, MD Andrew D Zelenetz, MD, PhD
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York

  
  Click here to download the entire interview  
Track 1 Long-term results from GELA: R-CHOP versus CHOP in older patients with diffuse large B-cell
lymphoma (DLBCL)
Track 2 Intergroup study of maintenance rituximab following R-CHOP or CHOP in older patients with DLBCL
Track 3 Clinical use of CHOP and rituximab in patients with HIV-related lymphoma
Track 4 Maintenance rituximab in patients with DLBCL
Track 5 Clinical trial evidence for the use of maintenance rituximab in low-grade lymphomas
Track 6 Differential outcomes with maintenance rituximab in indolent and aggressive lymphomas

Track 7 Maintenance rituximab in ongoing clinical trials
Track 8 Continuation of rituximab beyond disease progression
Track 9 Clinical trials of maintenance rituximab after initial therapy for indolent lymphoma
Track 10 Practical application of maintenance rituximab in follicular lymphoma
Track 11 Validation of the Follicular Lymphoma International Prognostic Index (FLIPI) among patients treated
with rituximab
Track 12 Survival benefit with combined modality therapy in Hodgkin’s lymphoma
Track 13 Biomarkers to develop risk-adapted treatment strategies for patients with DLBCL
Track 14 PET scans following dose-dense R-CHOP in patients with DLBCL
Track 15 RICOVER-60 trial: Six versus eight cycles of dose-dense CHOP-14 with or without rituximab in DLBCL
Track 16 Tolerability of the R-CHOP-14 regimen
Track 17 Tositumomab and I-131 tositumomab (Bexxar®) in combination with stem cell transplantation for
relapsed DLBCL
Track 18 Role of radioimmunotherapy in patients with mantle-cell lymphoma
Track 19 Treatment strategies for patients with mantle-cell lymphoma
     
Leonard, MD John P Leonard, MD
Clinical Director, Center for Lymphoma and Myeloma
Professor of Medicine
Weill Medical College of Cornell University
New York Presbyterian Hospital
New York, New York
  
  Click here to download the entire interview  
Track 1 Phase II trial of bortezomib in combination with R-CHOP in patients with DLBCL
Track 2 Ongoing clinical trials for patients with DLBCL
Track 3 Clinical trials of bevacizumab in patients with lymphoma
Track 4 Rationale for combining bortezomib with R-CHOP
Track 5 Clinical use of PET scans for patients with lymphoma
Track 6 Clinical trials with galiximab and lumiliximab

Track 7 Non-Hodgkin’s lymphoma: Highlights from ASCO 2007
Track 8 Clinical use of maintenance rituximab in patients with follicular lymphoma
Track 9 Novel agents in the treatment of mantle-cell lymphoma
Track 10 Ongoing clinical trials in mantle-cell lymphoma
Track 11 Management of mantle-cell lymphoma
Track 12 Vaccine trials for patients with indolent lymphoma
Track 13 Management of indolent lymphoma
audio
Track 14 Current trials evaluating consolidation radioimmunotherapy after chemotherapy
audio
Track 15 Clinical use of radioimmunotherapy
audio
Track 16 Advances in the treatment of chronic lymphocytic leukemia
audio
Track 17 Challenging issues in the management of lymphoma
audio
Track 18 Approach to patients with relapsed large B-cell lymphoma
audio
     
Maloney, MD David G Maloney, MD, PhD
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Associate Professor of Medicine, Division of Oncology
University of Washington
Seattle, Washington

  
  Click here to download the entire interview  
Track 1 Clinical treatment strategy for advanced stage follicular lymphoma
Track 2 Benefit of adding rituximab to chemotherapy for patients with follicular lymphoma
Track 3 “Watch and wait” versus treatment for patients with follicular lymphoma
Track 4 Use of immune response signatures as an indicator of prognosis
Track 5 ECOG-E4402: Rituximab Extended Schedule Or Re-Treatment (RESORT) trial
Track 6 Clinical utility of single-agent rituximab for patients with follicular lymphoma

Track 7 SWOG-S0016: CHOP with either rituximab or Bexxar in follicular lymphoma
Track 8 Clinical use of maintenance rituximab for follicular lymphoma
Track 9 PRIMA study: Maintenance rituximab after response to R-chemotherapy in advanced follicular lymphoma
Track 10 Rituximab maintenance with front-line chemotherapy
Track 11 Side effects associated with maintenance rituximab
audio
Track 12 Autologous stem cell transplant for patients with relapsed follicular lymphoma
audio
Track 13 Diagnosing transformation from indolent to aggressive lymphoma
audio
Track 14 Allogeneic stem cell transplantation for follicular lymphoma
audio
Track 15 Treatment strategies for mantle-cell lymphoma
audio
Track 16 Allogeneic stem cell transplantation for mantle-cell lymphoma
audio
Track 17 R-CHOP as induction therapy for DLBCL
audio
Track 18 Clinical trial of dose-adjusted EPOCH-R
audio
Track 19 Role of PET scans in patients with DLBCL
audio
Track 20 ASCO 2007: Non-Hodgkin’s lymphoma highlights
audio